CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 2% – What’s Next?

CRISPR Therapeutics AG (NASDAQ:CRSP)’s stock price dropped 2% on Friday . The stock traded as low as $49.31 and last traded at $49.44. Approximately 584,895 shares traded hands during trading, a decline of 75% from the average daily volume of 2,371,877 shares. The stock had previously closed at $50.43.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, February 13th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a report on Wednesday, February 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. The Goldman Sachs Group reduced their price target on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Finally, Stifel Nicolaus decreased their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $74.40.

CRISPR Therapeutics Trading Down 5.2 %

The firm has a 50 day simple moving average of $42.16 and a 200 day simple moving average of $46.07. The firm has a market capitalization of $4.10 billion, a PE ratio of -10.94 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Research analysts forecast that CRISPR Therapeutics AG will post -5.03 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Blue Trust Inc. lifted its position in CRISPR Therapeutics by 158.7% in the third quarter. Blue Trust Inc. now owns 3,844 shares of the company’s stock worth $181,000 after buying an additional 2,358 shares during the last quarter. Eastern Bank purchased a new position in CRISPR Therapeutics during the 3rd quarter valued at about $70,000. International Assets Investment Management LLC purchased a new stake in CRISPR Therapeutics during the third quarter worth $1,825,000. Hennion & Walsh Asset Management Inc. grew its stake in CRISPR Therapeutics by 15.9% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 40,568 shares of the company’s stock valued at $1,906,000 after purchasing an additional 5,567 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in CRISPR Therapeutics by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,080 shares of the company’s stock worth $146,000 after purchasing an additional 545 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.